NASDAQ : BIIB
Biogen Inc. — Key statistics
Healthcare · Drug Manufacturers - General · United States
Last price 254.07 USD (Oct 30, 2026, 3:53 PM EDT) · Market cap 37.56B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 37.49B |
| Enterprise Value | 43.99B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 147.82M |
| Shares Outstanding | 147.82M |
| Shares Change (YoY) | +1.49% |
| Shares Change (QoQ) | -0.61% |
| Owned by Insiders (%) | 0.21% |
| Owned by Institutions (%) | 97.95% |
| Float | 147.29M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 108.56 |
| Forward PE | 17.19 |
| PS Ratio | 3.64 |
| Forward PS | 3.54 |
| PB Ratio | 1.98 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.11 |
| P/OCF Ratio | 16.68 |
| PEG Ratio | 1.83 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 126.58 |
| EV / Sales | 4.27 |
| EV / EBITDA | 13.32 |
| EV / EBIT | 18.17 |
| EV / FCF | 21.24 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.95 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 2.28 |
| Debt / FCF | 3.77 |
| Interest Coverage | 7.94 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 1.87% |
| Return on Assets (ROA) | 4.94% |
| Return on Invested Capital (ROIC) | 7.36% |
| Return on Capital Employed (ROCE) | 8.60% |
| Weighted Average Cost of Capital (WACC) | 4.46% |
| Revenue Per Employee | $1.37M |
| Profits Per Employee | $46,333 |
| Employee Count | 7,500 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 1.13 |
Taxes
| Measure | Value |
|---|
| Income Tax | 97.60M |
| Effective Tax Rate | 21.93% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.09 |
| 52-Week Price Change | +71.53% |
| 50-Day Moving Average | 227.08 |
| 200-Day Moving Average | 201.18 |
| Relative Strength Index (RSI) | 66.65 |
| Average Volume (20 Days) | 1,337,909 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.50M |
| Short Previous Month | 5.97M |
| Short % of Shares Out | 3.72% |
| Short % of Float | 3.73% |
| Short Ratio (days to cover) | 4.46 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 10.30B |
| Gross Profit | 7.80B |
| Operating Income | 2.42B |
| Pretax Income | 445.10M |
| Net Income | 347.50M |
| EBITDA | 3.30B |
| EBIT | 2.42B |
| Earnings Per Share (EPS) | $2.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.30B |
| Total Debt | 7.80B |
| Net Cash | -6.50B |
| Net Cash Per Share | -$43.95 |
| Equity (Book Value) | 18.92B |
| Book Value Per Share | 128.03 |
| Working Capital | 3.69B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 2.25B |
| Capital Expenditures | -176.40M |
| Depreciation & Amortization | 881.80M |
| Net Borrowing | 623.30M |
| Free Cash Flow | 2.07B |
| FCF Per Share | $14.01 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.77% |
| Operating Margin | 23.50% |
| Pretax Margin | 4.32% |
| Profit Margin | 3.37% |
| EBITDA Margin | 32.07% |
| EBIT Margin | 23.50% |
| FCF Margin | 20.11% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.49% |
| Shareholder Yield | -1.49% |
| Earnings Yield | 0.92% |
| FCF Yield | 5.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $264.23 |
| Price Target Difference | 4.18% |
| Analyst Consensus | Buy |
| Analyst Count | 36 |
| Revenue Growth Forecast (3Y) | 3.84% |
| EPS Growth Forecast (3Y) | 6.44% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.89 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |